Chia, S. K. L., Redfern, A. D., Ayoub, J. M., Chalchal, H. I., Rayson, D., Rushton, M., Desbiens, C., Sabanathan, D., Raphael, J., Chan, A., Singh, J., Simmons, C. E., Zdenkowski, N., Wilson, S., Rodin, D., Cescon, D. W., Schimmoller, F., Gallinaro, L., Chen, B. E., Parulekar, W. R. (2025). A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba1005